Paul Reider - 02 Jan 2024 Form 4 Insider Report for Coherus BioSciences, Inc. (CHRS)

Role
Chief Commercial Officer
Signature
/s/ Bryan McMichael, as Attorney-in-Fact for Paul Reider
Issuer symbol
CHRS
Transactions as of
02 Jan 2024
Net transactions value
$0
Form type
4
Filing time
04 Jan 2024, 17:13:16 UTC
Previous filing
15 Dec 2023
Next filing
08 Jan 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CHRS Stock Option (Right to Buy) Award $0 +160,000 $0.000000 160,000 02 Jan 2024 Common Stock 160,000 $3.14 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/48th of the total number of shares subject to the option shall vest in successive, equal monthly installments measured from January 2, 2024, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.